MSLN and ovarian cancer: Taking advantage of the high-affinity interaction between mesothelin and the MUC16 biomarker located on ovarian cancer cell membranes [15], we designed a mesothelin/TR3 fusion protein [16], and subsequently a more potent and stabilized truncation variant, Meso64TR3 [17].